{"protocolSection":{"identificationModule":{"nctId":"NCT06210646","orgStudyIdInfo":{"id":"2391988"},"organization":{"fullName":"Kafrelsheikh University","class":"OTHER"},"briefTitle":"Citicoline in Ischemic Stroke, a Randomized Trial","officialTitle":"Citicoline in Ischemic Stroke, a Randomized Placebo-controlled Trial"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-12-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06-29","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-29","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-01-07","studyFirstSubmitQcDate":"2024-01-07","studyFirstPostDateStruct":{"date":"2024-01-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-07","lastUpdatePostDateStruct":{"date":"2024-01-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Mohamed G. zeinhom, MD","investigatorTitle":"Dr.","investigatorAffiliation":"Kafrelsheikh University"},"leadSponsor":{"name":"Kafrelsheikh University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"Along with the current clinical trial, the efficacy and safety of a 1000 mg daily citicoline administered within 24 hours of the first-ever ischemic stroke and lasted 12 months compared to placebo were assessed through MoCA, NIHSS, mRS, and possible adverse effects.","detailedDescription":"The investigators conducted a single-blinded, placebo-controlled, randomized controlled trial between December 2023 and December 2024 after approval of the ethical committee of the faculty of medicine at Kafr el-Sheik University.\n\nThe investigators got written informed consent from all eligible patients or their first order of kin before randomization.\n\nThe study will comprise 2 arms citicoline arm, which consists of 400 patients who received 1000 mg citicoline once daily for 12 months, and the placebo arm, consisting of 400 patients who received a placebo once daily for 12 months; all the patients in the two groups received open-label double antiplatelet in the form of 75 mg aspirin. and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.\n\nStudy Procedures:\n\nEvery patient in our study will undergo:\n\nclinical workup: History, clinical assessment \\& NIHSS, and the Modified Rankin Scale and MoCA scale were recorded at baseline and then after 3 months, 6 months, and 12 months as a follow-up\n\nDetection of Risk Factors \\& Profiles:\n\nEchocardiography TTE: in indicated patients ECG Monitoring: daily ECG monitoring will be performed in indicated patients. 3- Carotid Duplex: carotid duplex in indicated patients.\n\n4- ESR \\& Lipid Profile\\& liver functions: All will be tested routinely for all patients.\n\nImaging Follow UP Non-contrast CT brain on admission and MRI (stroke protocol; T1W, T2W, FLAIR, DWI, T2 Echo Gradient, MRA of all intra-cerebral vessels).\n\nCT brain: Any patient with unexplained clinical deterioration at any time throughout his/her hospital stay will be urgently imaged by CT.\n\nPrimary End Point:\n\nThe primary efficacy outcome was the MoCA score after 6 months, the primary safety outcome was the rate of treatment-related adverse effects assessed by a follow-up questionnaire after 6 months.\n\n• Secondary End Point: the secondary efficacy outcomes were: the MoCA after 12 months, mRS after 6 months, and mRS after 12 months, and the secondary safety outcome was the rate of treatment-related adverse effects assessed by a follow-up questionnaire after 12 months."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["citicoline","ischemic stroke","Egypt"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"We will conduct our randomized controlled trial, which will contain 2 arms; the citicoline arm, which consists of 400 patients who received 1000 mg citicoline once daily for 12 months, and the placebo arm, consisting of 400 patients who received a placebo capsule once daily for 12 months; both groups will receive open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","maskingDescription":"An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, a specially trained and qualified nurse randomly assigned participants to receive either citicoline or a placebo. We prepared Sequentially numbered opaque sealed envelopes and 800 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 800. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included citicoline, and Drug B included a placebo. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.","whoMasked":["PARTICIPANT","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":800,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"citicoline arm","type":"ACTIVE_COMPARATOR","description":"The citicoline arm consists of 400 patients who received 1000 mg citicoline once daily for 12 months and an open-label double antiplatelet in the form of 75 mg aspirin and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.","interventionNames":["Drug: Citicoline"]},{"label":"placebo arm","type":"PLACEBO_COMPARATOR","description":"The placebo arm consists of 400 patients who received a placebo capsule daily for 12 months and an open-label double antiplatelet in the form of 75 mg aspirin and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Citicoline","description":"The citicoline arm consists of 400 patients who received 1000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.","armGroupLabels":["citicoline arm"],"otherNames":["group A"]},{"type":"DRUG","name":"Placebo","description":"The placebo arm consists of 400 patients who received a placebo capsule once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.","armGroupLabels":["placebo arm"],"otherNames":["group B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Value of Montreal Cognitive Assessment (MoCA)","description":"MoCA is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.\n\nIts score ranges from zero to 30 points; the normal value is from 26 to 30; mild cognitive impairment ranges from 18 to 25, Moderate cognitive impairment ranges from 10 to 17, and severe cognitive impairment is below 10 points.","timeFrame":"6 months"},{"measure":"Rate of drug-related complications after 6 months","description":"All side effects related to the drugs in our study will be reported","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Value of Montreal Cognitive Assessment (MoCA)","description":"MoCA is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.\n\nIts score ranges from zero to 30 points; the normal value is from 26 to 30; mild cognitive impairment ranges from 18 to 25, Moderate cognitive impairment ranges from 10 to 17, and severe cognitive impairment is below 10 points.","timeFrame":"12 months"},{"measure":"Value of Modified Rankin Scale (mRS) at 6 months","description":"mRS Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability; its value ranges from 0 to 6; the lower the score, the better the stroke outcome; favorable stroke outcome is considered with mRS value equals two or less.","timeFrame":"6 months"},{"measure":"Value of Modified Rankin Scale (mRS) at 12 months","description":"mRS Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability; its value ranges from 0 to 6; the lower the score, the better the stroke outcome; favorable stroke outcome is considered with mRS value equals two or less.","timeFrame":"12 months"},{"measure":"Rate of drug-related complications after 12 months","description":"All side effects related to the drugs in our study will be reported","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male \\& female patients will be included\n* Age more than 18 years.\n* Patients must be treated within the first 24 hours of their initial stroke symptoms onset.\n* Patients not eligible to receive TPA.\n* Patients with a measurable focal neurological deficit (NIHSS score ≥ 4 and less than 21) lasting at least 60 minutes.This deficit must persist from the onset and up to the time of treatment without clinically significant improvement\n\nExclusion Criteria:\n\n* Patients eligible for rTPA treatment.\n* Patients with any type of aphasia\n* Patients in coma: patients having a score of 2 or higher in the items regarding the level of consciousness in the NIHSS.\n* CT or conventional MRI evidence of any structural brain disorder other than ischemic stroke.\n* History of ventricular dysrhythmias, acute myocardial infarction within 72 hours before enrolment, unstable angina, decompensated congestive heart failure, or any other acute, severe, uncontrollable, or sustained cardiovascular condition that, in the Investigator's opinion, may interfere with effective participation in the study.\n* Previous disorders that may confound the interpretation of the neurological scales.\n* Drug addiction-related disorders.\n* Pre-existing dementia, when dementia implies a disability, measured as a score of 2 or higher in the previous mRS.\n* Patients under current treatment with citicoline.\n* concomitant administration of other neuroprotectant drugs (such as nimodipine, vinpocetine, piracetam, cerebrolysine).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"mohamed G Zeinhom, MD","role":"CONTACT","phone":"2001009606828","email":"mohamed_gomaa@med.kfs.edu.eg"},{"name":"sherihan R. ahmed, MD","role":"CONTACT","phone":"2001113432342","email":"sherihanrezk2016@gmail.com"}],"overallOfficials":[{"name":"mohamed G. Zeinhom, MD","affiliation":"neurology department kafr el-sheikh university","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Kafr Elsheikh University Hospital","status":"RECRUITING","city":"Kafr Ash Shaykh","zip":"33511","country":"Egypt","contacts":[{"name":"mohamed G. Zeinhom, MD","role":"CONTACT","phone":"2001009606828","email":"mohamed_gomaa@med.kfs.edu.eg"},{"name":"sherihan R ahmed, MD","role":"CONTACT","phone":"2001007481842","email":"sherihanrezk2016@gmail.com"}],"geoPoint":{"lat":31.11174,"lon":30.93991}}]},"referencesModule":{"references":[{"pmid":"16731270","type":"BACKGROUND","citation":"Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006 May 27;367(9524):1747-57. doi: 10.1016/S0140-6736(06)68770-9."},{"pmid":"12271462","type":"RESULT","citation":"Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002 Oct 15;70(2):133-9. doi: 10.1002/jnr.10403."},{"pmid":"19536360","type":"RESULT","citation":"Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):171-6. doi: 10.1358/mf.2009.31.3.1364241."},{"pmid":"20875651","type":"RESULT","citation":"Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010 Dec 15;299(1-2):188-92. doi: 10.1016/j.jns.2010.08.027. Epub 2010 Sep 27."}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"All the data that support the findings of this research will be available from the corresponding author M. Zeinhom upon reasonable request."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003566","term":"Cytidine Diphosphate Choline"}],"ancestors":[{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M1669","name":"Clopidogrel","relevance":"LOW"},{"id":"M6461","name":"Cytidine Diphosphate Choline","asFound":"Rod","relevance":"HIGH"},{"id":"M5724","name":"Choline","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"},{"id":"T443","name":"Choline","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"Gast","name":"Gastrointestinal Agents"},{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":false}